Contineum Therapeutics Shares Surge 27% After Bristol Myers Squibb Reports Positive Phase 3 Trial Results
Yahoo Finance · Oct 12, 2026 · Contineum Therapeutics, Inc. Class A Common Stock (CTNM)
Contineum Therapeutics (NASDAQ:CTNM) shares climbed 27% in premarket trading on Monday after Bristol Myers Squibb (NYSE:BMY) reported positive Phase 3 clinical trial results for a pulmonary fibrosis treatment targeting the same biological pathway as Contineum’s lead drug candidate. Contineum shares were indicated at $16.
Not investment advice. Headline and summary only, not a full reprint.